Schorno Dean L 4

4 · RIGEL PHARMACEUTICALS INC · Filed Dec 29, 2025

Form 4

Period: 2025-12-22

EVP & Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2025-12-22$20.00/sh+1,987$39,740→ 59,722 total
Exercise/Conversion
Common Stock
[F1]
2025-12-22$24.20/sh+2,846$68,873→ 62,568 total
Exercise/Conversion
Common Stock
[F1]
2025-12-22$18.70/sh+1,667$31,173→ 64,235 total
Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F3]
2025-12-22−1,987→ 14,262 total
Exercise: $20.00Exp: 2029-01-23→ Common Stock (1,987 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F4]
2025-12-22−2,846→ 17,153 total
Exercise: $24.20Exp: 2030-02-06→ Common Stock (2,846 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F5]
2025-12-22−1,667→ 10,832 total
Exercise: $18.70Exp: 2033-01-26→ Common Stock (1,667 underlying)

Footnotes (5)

[F1]These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
[F2]Includes 500 shares of common stock acquired under the Issuer's stock purchase plan.
[F3]The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period.
[F4]The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period.
[F5]The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

Signature

/s/ Raymond Furey (Attorney-in-Fact)|2025-12-29

Documents

1 file